Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: Implication for MEK-ERK pathway activation

Marta Lionetti, Marzia Barbieri, Katia Todoerti, Luca Agnelli, Simona Marzorati, Sonia Fabris, Gabriella Ciceri, Serena Galletti, Giulia Milesi, Martina Manzoni, Mara Mazzoni, Angela Greco, Giovanni Tonon, Pellegrino Musto, Luca Baldini, Antonino Neri

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma (MM) is a clinically and genetically heterogeneous plasma cell (PC) malignancy. Whole-exome sequencing has identified therapeutically targetable mutations such as those in the mitogen-activated protein kinase (MAPK) pathway, which are the most prevalent MM mutations. We used deep sequencing to screen 167 representative patients with PC dyscrasias [132 with MM, 24 with primary PC leukemia (pPCL) and 11 with secondary PC leukemia (sPCL)] for mutations in BRAF, NRAS and KRAS, which were respectively found in 12%, 23.9% and 29.3% of cases. Overall, the MAPK pathway was affected in 57.5% of the patients (63.6% of those with sPCL, 59.8% of those with MM, and 41.7% of those with pPCL). The majority of BRAF variants were comparably expressed at transcript level. Additionally, gene expression profiling indicated the MAPK pathway is activated in mutated patients. Finally, we found that vemurafenib inhibition of BRAF activation in mutated U266 cells affected the expression of genes known to be associated with MM. Our data confirm and extend previous published evidence that MAPK pathway activation is recurrent in myeloma; the finding that it is mediated by BRAF mutations in a significant fraction of patients has potentially immediate clinical implications.

Original languageEnglish
Pages (from-to)24205-24217
Number of pages13
JournalOncotarget
Volume6
Issue number27
DOIs
Publication statusPublished - 2015

Keywords

  • BRAF
  • Multiple myeloma
  • Next generation sequencing
  • Plasma cell leukemia
  • RAS

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: Implication for MEK-ERK pathway activation'. Together they form a unique fingerprint.

Cite this